Abstract
T riglyceride deposit cardiomyovasculopathy (TGCV) is a
novel clinical entity we found in Japanese patients waiting for heart transplant in 2008 (1, 2) . In TGCV, abnormal intracellular metabolism renders cells incapable of using long-chain fatty acids (LCFAs) (3, 4) (Fig. 1) , which play major roles in producing ATP in normal heart. TGCV is characterized by the ectopic accumulation of TG in cardiomyocytes (5) and vascular smooth muscle cells (SMCs) (6) ( Fig. 2 ) that in turn causes pathological conditions such as severe heart failure, coronary artery disease, and arrhythmias.
Tissue TG contents in TGCV are not always correlated with BMI, body weight, and obesity which reflect the degree of TG accumulation in adipose tissues, which store TG in physiological conditions. In addition, it has no direct relationship with Annals of Nuclear Cardiology J-STAGE Advance published date: August 23, 2017 doi: 10.17996/anc. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] plasma TG levels, because regulatory mechanism and responsible enzymes are different intracellularly from those in plasma (7) . The probands for TGCV carried genetic mutations in the adipose triglyceride lipase (ATGL), which is the ratelimiting enzyme for hydrolysis of intracellular TG (8) . Gene targeting in mice showed massive cardiomyocyte steatosis and premature death (9) . Human genetic ATGL deficiency (10, 11) has turned out to be ultra-rare (12) and only 47 patients identified globally, since we launched the Japan TGCV study group in 2009. However, our postmortem analyses (13, 14) for subjects who died of cardiovascular diseases demonstrated that substantial numbers of autopsied individuals showed TGCV phenotype, most of who had suffered from diabetes mellitus. The amount of triglycerides in the coronary artery of patients who died of cardiovascular complications was several times higher in diabetic patients than in non-diabetic patients.
In addition, we reported cardiomyocyte steatosis and reduced expression of myocardial ATGL in a diabetic model, db/db mouse (15) . Based upon these observations, we think that TGCV might be difficult to diagnose in daily clinics, however be more prevalent than expected, and a possible important cause of cardiac death. This review article focuses on imaging modalities which are useful for the diagnosis of TGCV and discuss about future perspectives. (16) (Fig. 3) . ATGL deficiency manifesting skeletal muscle myopathy (mild to severe) is called neutral lipid storage disease with myopathy (NLSD-M) (10, 11) . The phenotype of heterozygotes is currently unknown, and our study group is conducting research on that topic.
Classification and epidemiology of TGCV

Idiopathic TGCV
This type of TGCV was found by retrospective postmortem analysis of hearts autopsied after cardiac death (Fig. 4) (13, 14) . As with primary TGCV, patients with idiopathic TGCV also exhibit triglyceride accumulation in cardiac muscle and 
Cardiac morphology
As we reviewed literatures, 38% of patients with genetic deficiency showed symptomatic cardiac involvements (12) .
We reported that even homozygous siblings with the same mutation showed distinct cardiac phenotype; one showed DCM-like and the other showed HCM-like phenotypes (16). (18) with TG accumulation have pro-inflammatory and vulnerable characteristics, including increased NF-ĸB signaling, increased expression of interleukin-6, TNFα, and decreased expression of collagen type I.
Conceptual difference between TGCV and other diabetic and metabolic heart diseases
There have been known some disease concepts which need to be differentiated from TGCV: one is diabetic cardiomyopathy which was originally defined as cardiomyopathy without significant stenosis in epicardial coronary arteries.
Another is fat accumulation in the epicardial adipose tissue, which is the over-deposition of TG in physiological tissue.
TGCV is distinct from these two entities, because TGCV is characterized by the ectopic deposition of TG in cardiomyovascular systems with apparent involvement of epicardial coronary arteries.
Clinical symptoms for TGCV
The onset of TGCV is believed to appear in the adulthood and middle age. Patients complain of heart failure symptoms such as palpitations, shortness of breath, dyspnea on exertion, fatigability, edema, cough, weight gain, and frequent urination (particularly at night). The chest pain and chest tightness observed in patients with TGCV also occurs at rest and at night, and frequently is resistant to nitroglycerin tablets or nitrates. In some cases, arrhythmia causes symptoms such as pulse deficit, palpitations, and syncope. Many TGCV patients have a history of cardiopulmonary arrest, and there have also been reports of sudden death (16) .
Laboratory tests for TGCV
The pathology of TGCV is rooted in abnormal cellular metabolism, which means that abnormalities in metabolism of TG and LCFAs in affected organs and cells must be evaluated by testing. 
Electrocardiograms (ECG)
As shown in Fig. 3 , ECG reflects cardiac morphology and coronary involvement. There have been no specific findings for cardiomyovascular TG accumulation known.
Imaging modalities for evaluating myocardial TG accumulation
Ultrasonography
As shown in Fig. 3 , some patients showed DCM-like and (Fig. 7) (13, 23) . Table 2 summarized the laboratory tests and imaging modalities to detect myocardial TG deposition, even the number of genetic ATGL deficiency is ultra-rare and information is very limited.
As shown in Fig. 2 , abnormal intracellular metabolism of LCFAs is the major aspect for pathophysiology of TGCV, we think that BMIPP is useful for the diagnosis of this disorder.
Nuclear imagings with not only BMIPP but also other tracers such as 123-I-labeled meta-iodobenzylguanidine (MIBG) (24, 25) in patients with TGCV and other types of cardiomyopathy (26) 
Future perspectives
We previously found the concept "TGCV" in ultra-rare cases with genetic ATGL deficiency. The following studies indicate that this concept can be applied to commonlyobserved and intractable heart diseases. Because remedies 
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